Cargando…

Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy

Docetaxel is a well-known causative agent of nail alterations. The aim of this study was to reveal the impact of nail alterations associated with low-dose metronomic (LDM) docetaxel chemotherapy on the survival of non-small cell lung cancer (NSCLC) patients. Clinical information, survival data and n...

Descripción completa

Detalles Bibliográficos
Autores principales: KIBATA, KAYOKO, TAMAKI, TAKESHI, INAGAKI, NORIKO, OGATA, MAKOTO, SHIMIZU, TOSHIKI, NOMURA, SHOSAKU
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629050/
https://www.ncbi.nlm.nih.gov/pubmed/23599750
http://dx.doi.org/10.3892/ol.2013.1178
_version_ 1782266508367364096
author KIBATA, KAYOKO
TAMAKI, TAKESHI
INAGAKI, NORIKO
OGATA, MAKOTO
SHIMIZU, TOSHIKI
NOMURA, SHOSAKU
author_facet KIBATA, KAYOKO
TAMAKI, TAKESHI
INAGAKI, NORIKO
OGATA, MAKOTO
SHIMIZU, TOSHIKI
NOMURA, SHOSAKU
author_sort KIBATA, KAYOKO
collection PubMed
description Docetaxel is a well-known causative agent of nail alterations. The aim of this study was to reveal the impact of nail alterations associated with low-dose metronomic (LDM) docetaxel chemotherapy on the survival of non-small cell lung cancer (NSCLC) patients. Clinical information, survival data and nail alterations in patients treated with LDM docetaxel chemotherapy (docetaxel 15 mg/m(2) per week) were retrospectively reviewed. Forty-nine patients were included in this study. Various nail alterations were observed in 17 of the 49 patients (34.7%). Onycholysis and subungual hyperkeratosis were observed in 22.4% and 10.2% of patients, respectively. The number of docetaxel administration cycles was correlated with the incidence and severity of nail alterations. Univariate and multivariate analysis clearly demonstrated that the occurrence of nail alterations was an independent favorable prognostic factor for overall survival. Nail alterations associated with treatment may act as a surrogate marker for the efficacy of low-dose metronomic docetaxel chemotherapy.
format Online
Article
Text
id pubmed-3629050
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-36290502013-04-18 Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy KIBATA, KAYOKO TAMAKI, TAKESHI INAGAKI, NORIKO OGATA, MAKOTO SHIMIZU, TOSHIKI NOMURA, SHOSAKU Oncol Lett Articles Docetaxel is a well-known causative agent of nail alterations. The aim of this study was to reveal the impact of nail alterations associated with low-dose metronomic (LDM) docetaxel chemotherapy on the survival of non-small cell lung cancer (NSCLC) patients. Clinical information, survival data and nail alterations in patients treated with LDM docetaxel chemotherapy (docetaxel 15 mg/m(2) per week) were retrospectively reviewed. Forty-nine patients were included in this study. Various nail alterations were observed in 17 of the 49 patients (34.7%). Onycholysis and subungual hyperkeratosis were observed in 22.4% and 10.2% of patients, respectively. The number of docetaxel administration cycles was correlated with the incidence and severity of nail alterations. Univariate and multivariate analysis clearly demonstrated that the occurrence of nail alterations was an independent favorable prognostic factor for overall survival. Nail alterations associated with treatment may act as a surrogate marker for the efficacy of low-dose metronomic docetaxel chemotherapy. D.A. Spandidos 2013-04 2013-02-05 /pmc/articles/PMC3629050/ /pubmed/23599750 http://dx.doi.org/10.3892/ol.2013.1178 Text en Copyright © 2013, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
KIBATA, KAYOKO
TAMAKI, TAKESHI
INAGAKI, NORIKO
OGATA, MAKOTO
SHIMIZU, TOSHIKI
NOMURA, SHOSAKU
Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy
title Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy
title_full Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy
title_fullStr Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy
title_full_unstemmed Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy
title_short Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy
title_sort nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629050/
https://www.ncbi.nlm.nih.gov/pubmed/23599750
http://dx.doi.org/10.3892/ol.2013.1178
work_keys_str_mv AT kibatakayoko nailalterationsasasurrogatemarkerfortheefficacyoflowdosemetronomicchemotherapy
AT tamakitakeshi nailalterationsasasurrogatemarkerfortheefficacyoflowdosemetronomicchemotherapy
AT inagakinoriko nailalterationsasasurrogatemarkerfortheefficacyoflowdosemetronomicchemotherapy
AT ogatamakoto nailalterationsasasurrogatemarkerfortheefficacyoflowdosemetronomicchemotherapy
AT shimizutoshiki nailalterationsasasurrogatemarkerfortheefficacyoflowdosemetronomicchemotherapy
AT nomurashosaku nailalterationsasasurrogatemarkerfortheefficacyoflowdosemetronomicchemotherapy